Wall Street is neutral on Adverum Biotechnologies Inc (ADVM). On average, analysts give the stock a Buy rating. The average price target is $6, which means analysts expect the stock to increase by 219.15% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 13, which is better than 13% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ADVM a Buy today. Find out what this means to you and get the rest of the rankings on ADVM!
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions **before** a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Adverum Biotechnologies Inc Stock Today?
Adverum Biotechnologies Inc (ADVM) stock is higher by 6.82% while the S&P 500 is down -0.05% as of 11:14 AM on Wednesday, Dec 8. ADVM is higher by $0.12 from the previous closing price of $1.76 on volume of 329,508 shares. Over the past year the S&P 500 has gained 26.53% while ADVM is down -86.07%. ADVM lost -$1.52 per share the over the last 12 months.
Click Here to get the full Stock Report for Adverum Biotechnologies Inc stock.